Adverse events in patients treated with quinolones and fluoroquinolones before and after European Medicines Agency warning

Fluoroquinolone antibiotics – what we shouldn’t forget two years after the restriction by the European Commission

“…Another way to judge the impact of EC restrictions is to not only observe prescribing patterns and resistance rates, but to also look at reported adverse events. Analysis of the Eudra-Vigilance database of adverse events of fluoroquinolones revealed that reported total, musculoskeletal and connective tissue-related, and neurological adverse events were stable 21 month before and after the EC restriction [11]. The assessment of adverse events has several limitations as it is strongly dependent not only on the use of the medication but also on the awareness of adverse events or their extent.…”